Eris Lifesciences · NSE: ERIS · BSE: 540596
Q1 FY23 results · Apr–Jun 2022
Eris Lifesciences reported revenue from operations of ₹398.58 crore (up 14.1% from Q1 FY22) and net profit of ₹93.08 crore (down 12.7% from Q1 FY22) for Q1 FY23 (Apr–Jun 2022), on a consolidated basis.
| Item | Q1 FY23 | Q1 FY22 | YoY | Q4 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 398.58 | 349.27 | +14.1% | 305.95 | +30.3% |
| Other income | 2.74 | 5.87 | −53.3% | 8.06 | −66.0% |
| Total income | 401.32 | 355.13 | +13.0% | 314.01 | +27.8% |
| Profit before tax | 101.27 | 117.10 | −13.5% | 85.34 | +18.7% |
| Net profit for the period | 93.08 | 106.66 | −12.7% | 79.97 | +16.4% |
| Attributable to shareholders of the company | 94.58 | 106.66 | −11.3% | 80.30 | +17.8% |
| EPS, basic (₹) | 6.96 | 7.86 | −11.5% | 5.91 | +17.8% |
| Net margin (%) | 23.4 | 30.5 | 26.1 |
| Item | Q1 FY23 | Q1 FY22 | YoY | Q4 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 328.76 | 306.30 | +7.3% | 282.14 | +16.5% |
| Other income | 3.37 | 6.45 | −47.7% | 9.05 | −62.7% |
| Total income | 332.13 | 312.74 | +6.2% | 291.19 | +14.1% |
| Profit before tax | 107.36 | 117.30 | −8.5% | 94.63 | +13.5% |
| Net profit for the period | 95.59 | 106.72 | −10.4% | 86.71 | +10.2% |
| EPS, basic (₹) | 7.03 | 7.86 | −10.6% | 6.38 | +10.2% |
| Net margin (%) | 29.1 | 34.8 | 30.7 |
Consolidated
- Filed with BSE
- 08 Aug 2022, 15:01 IST
- Board meeting
- 05 Aug 2022
- Period
- 01 Apr 2022 to 30 Jun 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 08 Aug 2022, 15:01 IST
- Board meeting
- 05 Aug 2022
- Period
- 01 Apr 2022 to 30 Jun 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE